Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
225Ac-ABD147 in SCLC and LCNEC
NCT06736418Phase 1Active, not recruiting
- Sponsor
- Abdera Therapeutics
- Start
- Mar 2025
- Primary completion
- Aug 2026
- Modality
- Nanobodies (VHH), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ABD-147 in small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) (2 arms), sponsored by Abdera Therapeutics. Primary endpoints: Number and Grade of Adverse Events at 12 months, Number of Dose Limiting Toxicities at 12 months and 9 more. Started Mar 2025; status: active, not recruiting.
02
Drugs
ABD-147
03
Conditions
small cell lung cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)
Beyond the preview
Go deeper on NCT06736418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06736418.